[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
3. Fatimi SH, Shahid B, Hanif HM, Muzaffar M: Mediastinal seminoma presenting as superior vena cava syndrome and tracheal obstruction. J Pak Med Assoc; 2010 Oct;60(10):861-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal seminoma presenting as superior vena cava syndrome and tracheal obstruction.
  • Malignant germ cell tumours of the mediastinum are rare, presenting mostly in young males.
  • Occasionally, mediastinal adenopathy and superior vena cava (SVC) syndrome may occur.
  • CT scan chest showed a large mediastinal mass 18 x 24 cm extending from the superior mediastinum to the mid pericardial area.
  • The trachea was extrinsically compressed to almost 80% at its distal portion.
  • Surgery followed by radiation therapy has been the usual initial treatment with multimodal chemotherapy showing remarkable results.
  • [MeSH-major] Airway Obstruction / etiology. Mediastinal Neoplasms / pathology. Seminoma / pathology. Superior Vena Cava Syndrome / etiology. Tracheal Diseases / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Humans. Male. Sternotomy. Tomography, X-Ray Computed. Treatment Outcome. Young Adult


Advertisement
4. Tahri A, Sahraoui S, Bouras N, Benchekroun N, Acharki A, Benider A, Kahlain A: [Primitive seminoma of the mediastinum: a case report]. Ann Urol (Paris); 2001 Jan;35(1):64-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive seminoma of the mediastinum: a case report].
  • In this study, the case has been reported of a 36-year old male who was treated at the Ibn Rochd Oncology Center in Casablanca for a primary mediastinal seminoma revealed by a symptomatology including cough, dyspnea, laterocervical swelling, rachidial pain and gait disorder.
  • The preliminary investigation showed significant mediastinal enlargement with a right pleuritis and vertebral metastases; tumor markers were normal.
  • The diagnosis of seminoma was confirmed by pathological and immunohistochemical analysis of the cervical adenopathy.
  • Disease management consisted of BEP/cisplatin type chemotherapy and lumbar, mediastinal, and supraclavicular radiotherapy.
  • The response after four courses of combined chemo-/radiotherapy was estimated at 25%, but the patient died from respiratory failure five months after the initiation of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy. Seminoma / drug therapy. Seminoma / radiotherapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11233327.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


5. Iwasa S, Ando M, Ono M, Hirata T, Yunokawa M, Nakano E, Yonemori K, Kouno T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y: Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report. Jpn J Clin Oncol; 2009 Jul;39(7):456-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report.
  • This case report details a relapse with malignant transformation after the completion of bleomycin, etoposide and cisplatin chemotherapy for primary mediastinal seminoma, although the residual mass after chemotherapy was <3 cm in size and did not display an increased uptake of fluorodeoxyglucose when examined using positron emission tomography.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / drug therapy. Neoplasm Recurrence, Local / etiology. Seminoma / drug therapy
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fluorodeoxyglucose F18. Humans. Male. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395465.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Funahashi M, Tuchiya F, Makiyama K, Sugiura S, Miyoshi Y, Kishida T, Ogawa T, Uemura H, Yao M, Kubota Y: [Two cases of testicular tumors with high alpha-fetoprotein levels: a case report]. Hinyokika Kiyo; 2005 Feb;51(2):133-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis was an authentic stage I seminoma.
  • In 2002, chemotherapy was performed for a metastatic seminoma revealed as a solitary mass in the mediastinum by radiographic studies, and histologically confirmed to be a metastatic seminoma.
  • Case 2: In 2002, a 30-year-old male underwent left high orchiectomy for a left testicular tumor, and histological examination revealed seminoma, immature and mature teratoma, embryonal carcinoma.
  • Diagnosis was authentic stage I.
  • After 2 courses of chemotherapy, the serum AFP remained at an abnormally high concentration.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Embryonal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Seminoma / diagnosis. Teratoma / diagnosis. Testicular Neoplasms / diagnosis. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Orchiectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773370.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


7. Mountzios G, Pavlakis G, Terpos E, Sakorafas G, Revelos K, Bamias A, Nikolaou N, Papasavas P, Soria JC, Dimopoulos MA: Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours. BMC Clin Pathol; 2006;6:8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours.
  • Despite the initial disorientation of the diagnosis to a possible thyroid disorder, the patient underwent complete surgical resection of the mass revealing mediastinal choriocarcinoma.
  • Subsequent ultrasound of the scrotum indicated the presence of a small lobular node in the upper pole of the left testicle and the patient underwent radical left inguinal orchiectomy disclosing a typical seminoma.
  • Based on these results, the patient received 4 cycles of Bleomycin, Etoposide and Platinum chemotherapy experiencing only mild toxicity and resulting in complete ongoing clinical and biochemical remission.
  • Furthermore, urologists, pathologists and medical oncologists should be meticulous in the original pathological diagnosis in these patients, since there is a significant frequency of germ cell tumours with mixed or overlapping histological elements with diverse potential of evolution and differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2003 Jul;62(1):145 [12837454.001]
  • [Cites] Urology. 2004 Jan;63(1):176-8 [14751386.001]
  • [Cites] Ear Nose Throat J. 2004 May;83(5):356-9 [15195884.001]
  • [Cites] Mod Pathol. 2004 Dec;17(12):1573-80 [15545958.001]
  • [Cites] Urology. 2003 Jul;62(1):144 [12837446.001]
  • [Cites] Urology. 1989 Apr;33(4):320-1 [2929067.001]
  • [Cites] Br J Urol. 1995 Jun;75(6):797-8 [7613842.001]
  • [Cites] J Urol. 2003 Jun;169(6):2126-8 [12771733.001]
  • [Cites] Intern Med. 2004 Dec;43(12):1191-3 [15645657.001]
  • (PMID = 17112390.001).
  • [ISSN] 1472-6890
  • [Journal-full-title] BMC clinical pathology
  • [ISO-abbreviation] BMC Clin Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1697810
  •  go-up   go-down


8. Takeda S, Miyoshi S, Ohta M, Minami M, Masaoka A, Matsuda H: Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution. Cancer; 2003 Jan 15;97(2):367-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution.
  • BACKGROUND: Primary germ cell tumors (GCT) of the mediastinum share similar clinical and biologic characteristics, which are different from their testicular counterpart.
  • The purpose of the current study was to review the authors' institutional experience of mediastinal GCT, emphasizing the clinical spectrum, time trends of treatment, and recent advances in therapeutic modalities for malignant GCT.
  • METHODS: Between 1951 and 2000, 129 patients (70 males and 59 females) underwent surgical treatment for GCT, which accounted for 16.0% of the mediastinal tumors during the same period.
  • Eight of the 13 patients (61.5%) with seminoma were symptomatic and 10 of 13 patients (83.3%) survived after surgery and radiation with/without chemotherapy.
  • After 1986, six of eight patients received cisplatin-based chemotherapy, including three who received additional high-dose chemotherapy with a supporting peripheral blood stem cell transplantation until tumor markers normalized.
  • CONCLUSIONS: The institutional experience indicates the benign nature of mediastinal mature teratomas and the excellent prognosis for patients with seminomas after resection.
  • An improved survival advantage was ensured with cisplatin-based preoperative chemotherapy in patients with NSGCT.
  • [MeSH-major] Mediastinal Neoplasms. Neoplasms, Germ Cell and Embryonal
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Japan. Male. Middle Aged. Seminoma / diagnosis. Seminoma / epidemiology. Seminoma / therapy. Survival Analysis. Teratoma / diagnosis. Teratoma / epidemiology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society
  • (PMID = 12518361.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Hartmann JT: Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol; 2002 Apr 1;20(7):1864-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.
  • PURPOSE: To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies.
  • PATIENTS AND METHODS: Of an unselected population of 635 consecutive patients treated from 1975 through 1996 at 11 cancer centers, 341 patients (54%) had primary mediastinal EGCT, and 283 patients (45%) had retroperitoneal EGCT.
  • RESULTS: After platinum-based induction chemotherapy with or without secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow-up, 19 months; range, 1 to 178 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow-up, 29 months; range, 1 to 203 months) are alive (P =.0006).
  • In contrast, the overall survival rate for patients with a seminomatous EGCT is 88%, with no difference between patients with mediastinal or retroperitoneal tumor location (median follow-up, 49 months; range, 4 to 193 months; respective 70 months; range, 1 to 211 months).
  • A significantly lower progression-free survival rate was found in seminoma patients treated with initial radiotherapy alone compared with chemotherapy.
  • Nonseminomatous histology, presence of nonpulmonary visceral metastases, primary mediastinal GCT location, and elevated beta-human chorionic gonadotropin were independent prognostic factors for shorter survival.
  • Hematologic malignancies (n = 17) occurred without exception in patients with primary mediastinal nonseminoma.
  • Sixteen patients developed a metachronous testicular cancer despite the use of platinum-based chemotherapy.
  • CONCLUSION: Whereas patients with pure seminomatous EGCT histology have a long-term chance of cure of almost 90% irrespective of the primary tumor site, 45% of patients with mediastinal nonseminomas are alive at 5 years.
  • [MeSH-major] Germinoma / diagnosis. Germinoma / therapy. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / therapy. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Diagnosis, Differential. Europe. Female. Humans. Male. Medical Records. Middle Aged. Multivariate Analysis. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Salvage Therapy. Seminoma / diagnosis. Seminoma / therapy. Survival Analysis. Treatment Outcome. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11919246.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Landolsi A, Tarmiz H, Ben Fatma L, Kallel L, Gharbi O, Kraïem C, Korbi S, Ben Ahmed S: [Diagnosis and treatment of primary germ cell tumors of the mediastinum. Report of six cases]. Tunis Med; 2003 Jun;81(6):419-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary germ cell tumors of the mediastinum. Report of six cases].
  • [Transliterated title] Diagnostic et traitement des tumeurs germinales malignes primitives du mediastin. A propos de six cas.
  • Primary germ cell tumours of the mediastinum are rare.
  • The tumor site was the posterior mediastinum in two patients and anterior in the remaining cases.
  • At histologic exam we found two cases of seminoma, one embryonal carcinoma, one case of yolk sac tumor and two cases of composite tumor.
  • All patients had non metastatic but locally advanced disease at diagnosis.
  • Three patients were treated with cisplatin based chemotherapy followed by radiotherapy or surgical resection of residual masses.
  • [MeSH-major] Germinoma / diagnosis. Germinoma / therapy. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534949.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


13. Sakurai H, Asamura H, Suzuki K, Watanabe S, Tsuchiya R: Management of primary malignant germ cell tumor of the mediastinum. Jpn J Clin Oncol; 2004 Jul;34(7):386-92
Genetic Alliance. consumer health - Malignant germ cell tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary malignant germ cell tumor of the mediastinum.
  • BACKGROUND: Primary mediastinal malignant germ cell tumors (GCTs) are rare and have a worse prognosis than their gonadal counterparts.
  • Although multimodality treatment is a standard therapeutic strategy in mediastinal GCTs, the clinical implications of surgical intervention remain unclear.
  • METHODS: Forty-eight patients with primary mediastinal malignant GCT who were treated at the National Cancer Center Hospital, Tokyo, from 1962 to 2002 were studied retrospectively with regard to their histology and clinical profile.
  • RESULTS: Mediastinal GCT occurred predominantly in young males, with a mean age of 28.8 years at the time of diagnosis.
  • Histologically, seven patients (15%) were diagnosed as having pure seminoma and 41 (85%) had non-seminomatous GCT.
  • Treatment consisted of surgery alone in nine patients, surgery followed by chemotherapy in two, and chemotherapy followed by surgery in 20.
  • The other 17 patients received chemotherapy and/or radiotherapy without surgery.
  • Of these latter 17 patients, 14 developed progressive disease and three were followed up with a sustained partial response.
  • Among the 20 patients who received preoperative chemotherapy, viable cells were found in the resected specimen in six (30%).
  • CONCLUSIONS: Surgical intervention for mediastinal GCT may be needed to remove a chemotherapy-refractory tumor or to assess the pathological response to chemotherapy to determine the indications for further chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15342665.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Kamezaki K, Fukuda T, Makino S, Harada M: Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation. Intern Med; 2005 Feb;44(2):120-3
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation.
  • A 17-year-old man with mediastinal seminoma was treated with chemotherapy and mediastinal irradiation therapy.
  • Then he received high-dose chemotherapy containing cyclophosphamide (CY) followed by autologous peripheral blood stem cell transplantation.
  • It is suggested that the history of mediastinal irradiation was responsible for the onset of cardiomyopathy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Cardiomyopathies / chemically induced. Cyclophosphamide / adverse effects. Mediastinal Neoplasms / radiotherapy. Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Biopsy. Chemotherapy, Adjuvant / adverse effects. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Echocardiography. Humans. Magnetic Resonance Imaging. Male. Peripheral Blood Stem Cell Transplantation. Tomography, X-Ray Computed. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med. 2005 Feb;44(2):89-90 [15750266.001]
  • (PMID = 15750271.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


15. Fang FM, Ko SF, Hwang CH, Wang CJ: Healing of superior vena cava defect in mediastinal seminoma with invasion. Ann Thorac Surg; 2000 Aug;70(2):667-9
Genetic Alliance. consumer health - Seminoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing of superior vena cava defect in mediastinal seminoma with invasion.
  • We present an unusual case of mediastinal seminoma with direct intraluminal invasion into the superior vena cava (SVC) and extension to the right atrium.
  • Magnetic resonance imaging demonstration of the SVC defect due to tumor invasion was important for determining treatment strategy because rapid posttherapeutic tumor regression may increase the risk of SVC rupture.
  • Gradual healing of the SVC defect at the tumor entrance site was attained using a tailored treatment plan with radiotherapy and chemotherapy.
  • [MeSH-major] Heart Neoplasms / pathology. Mediastinal Neoplasms / pathology. Seminoma / pathology. Superior Vena Cava Syndrome / etiology
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Vena Cava, Superior / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969703.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Ayyanar K, Blackman SC, Chordas C, Frazier L, Kieran MW: Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent. J Pediatr Hematol Oncol; 2009 Nov;31(11):861-4
Genetic Alliance. consumer health - Seminoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent.
  • We report a case of a mediastinal seminoma occurring 19 months after the resolution of a pineal germinoma.
  • Radiation therapy leads to the resolution of his pineal germinoma and normalization of the beta-HCG.
  • A mediastinal seminoma (germinoma) was diagnosed nearly 2 years later because of rising serum beta-HCG.
  • The patient underwent systemic chemotherapy with the complete resolution of the mediastinal seminoma.
  • [MeSH-major] Germinoma / radiotherapy. Mediastinal Neoplasms / drug therapy. Neoplasms, Second Primary / drug therapy. Pinealoma / radiotherapy. Seminoma / drug therapy
  • [MeSH-minor] Adolescent. Chorionic Gonadotropin, beta Subunit, Human / blood. Chorionic Gonadotropin, beta Subunit, Human / cerebrospinal fluid. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779380.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


17. Abid L, Ayadi-Kaddour A, Braham E, Smati B, Ismail O, Kilani T, El Mezni F: [Primary mediastinal seminoma. Report of three cases]. Tunis Med; 2007 Jan;85(1):74-7
Genetic Alliance. consumer health - Seminoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mediastinal seminoma. Report of three cases].
  • [Transliterated title] Seminome primitif du mediastin. A propos de trois cas.
  • BACKGROUND: Primary mediastinal seminomas (PMS) are rare tumors that are morphologically similar to their testicular counterparts but may have different biologic behavior due to their particular anatomical location.
  • AIM: New cases report of PMS CASES: Three new cases of primary mediastinal seminoma are presented.
  • Mediastinoscopic biopsy was performed and histological examination results revealed a seminoma.
  • Chemotherapy has largely replaced surgical resection and radiotherapy as the initial treatment in patients with mediastinal seminoma.
  • [MeSH-major] Mediastinal Neoplasms. Seminoma
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Mediastinum / pathology. Middle Aged. Radiography, Thoracic. Radiotherapy Dosage. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17424717.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


18. Khan FY, Al Ani A, Allaithy MS, Al-Bozom IA: A young male with shortness of breath. Ann Thorac Med; 2008 Jan;3(1):28-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of primary mediastinal seminoma, which presented initially with shortness of breath and a swelling in upper part of anterior chest wall.
  • The diagnosis of primary mediastinal seminoma was established on the basis of histologic findings and was confirmed by immunohistochemical analysis.
  • Chemotherapy was initiated with B.E.P. protocol (Bleomycin, Etoposide, Cisplatinum); the patient received four cycles of chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Mar;165(3):908 [11176506.001]
  • [Cites] Ann Thorac Surg. 2000 Feb;69(2):337-43; discussion 343-4 [10735660.001]
  • [Cites] Am J Med. 1962 May;32:776-94 [13892927.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):142-4 [9544831.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):691-8 [9264352.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Lancet. 1994 May 7;343(8906):1130-2 [7910232.001]
  • [Cites] Ann Thorac Surg. 1987 Sep;44(3):229-37 [2820323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):835-41 [2550400.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1641-6 [1690077.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1877-82 [6793227.001]
  • [Cites] Am J Clin Pathol. 1976 Apr;65(4):450-4 [178171.001]
  • [Cites] Cancer. 1975 Sep;36(3):1162-8 [1237349.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):367-76 [12518361.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:265-72 [12401700.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1864-73 [11919246.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1394-401 [11283942.001]
  • (PMID = 19561881.001).
  • [ISSN] 1817-1737
  • [Journal-full-title] Annals of thoracic medicine
  • [ISO-abbreviation] Ann Thorac Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2700432
  • [Keywords] NOTNLM ; Extragonadal seminoma / mediastinal seminoma
  •  go-up   go-down


19. Zhou JF, Bai CM, Yang D, Chen SC: [Clinical analysis of primary mediastinal germ cell tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):531-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary mediastinal germ cell tumors].
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factor in primary mediastinal germ cell tumors (PMGCT).
  • METHODS: The clinical presentation, pathological features and therapeutic results of 29 patients with PMGCT were retrospectively analyzed.
  • RESULTS: All the 29 patients were male with a mean age of 26.1 +/- 9.6 years at diagnosis.
  • All tumors were originated from the anterior mediastinum with a mean diameter of 16.0 +/- 5.2 cm.
  • There were 5 (17.2%) primary mediastinal seminomas (PMSGCT) and 24 (82.8%) primary mediastinal nonseminomas (PMNSGCT) in this series.
  • Multimodality treatment consisting of cisplatin-based chemotherapy, surgery and radiotherapy was the principal therapy for PMGCT patients.
  • Cox multivariate analysis indicated that limited mediastinal disease at diagnosis (P = 0.004) and the use of cisplatin-based combined chemotherapy (P = 0.005) were independent good prognostic factors of PMNSGCT.
  • CONCLUSION: Primary mediastinal nonseminoma constitutes the most of primary mediastinal germ cell tumors.
  • Cisplatin-based combined chemotherapy may be the most effective for the treatment of primary mediastinal germ cell tumors.
  • The prognosis of primary mediastinal nonseminomas is significantly worse than that of primary mediastinal seminomas, and correlated with the extent of disease and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Seminoma / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / therapeutic use. Child. Cisplatin / therapeutic use. Combined Modality Therapy. Etoposide / therapeutic use. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Male. Mediastinum / surgery. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate. Taxoids / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069635.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; BEP protocol; TIP regimen
  •  go-up   go-down


20. Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Einhorn L, Nichols CR, Hartmann JT: Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer; 2001 Apr 1;91(7):1394-401
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
  • BACKGROUND: The objectives of this study were to evaluate the long term outcome of patients with extragonadal seminomatous germ cell tumors (GCT) so that prognostic variables for disease recurrence and patient survival could be identified and to access the efficacy of different treatment modalities.
  • METHODS: Six hundred thirty-five patients with extragonadal GCT who were treated consecutively at 11 centers in the United States and Europe during the cisplatin-based chemotherapy era between 1975 and 1996 were evaluated retrospectively.
  • RESULTS: Fifty-two patients with primary retroperitoneal GCT (50%) and 51 patients with primary mediastinal GCT (49%) of pure seminomatous histology were identified (n = 1 patient with a primary cervical lymph node) representing 16.4% of 635 patients with extragonadal GCT who were included in the data base.
  • Treatment consisted of platin-based chemotherapy in 77 patients (74%), radiotherapy in 9 patients (9%), and combined modality in 18 patients (17%).
  • Ninety-two percent of patients (95% confidence interval, 87-97%) achieved a favorable response to primary therapy.
  • After a median follow-up of 61 months (range, 1-211 months), 18 patients (17%) have had recurrent disease: 14% of those who received chemotherapy and 67% of those who received radiation therapy.
  • The 5-year progression free survival rate favored the chemotherapy group, with 87% compared with 33% for irradiated patients (P = 0.006), whereas the overall survival rates were equal (90% vs. 67%; P = 0.13).
  • No differences in overall survival or progression free survival were observed among patients with primary retroperitoneal and mediastinal seminoma.
  • CONCLUSIONS: In patients with extragonadal seminoma, a survival rate of > 90% at 5 years is achieved with adequate cisplatin-based chemotherapy.
  • Compared with patients with nonseminomatous extragonadal GCT, no difference in long term survival exists between patients with primary retroperitoneal or mediastinal seminoma location.
  • Primary radiotherapy seems to be associated with a significantly higher rate of disease recurrence, although most patients will be salvaged by subsequent chemotherapy.
  • [MeSH-major] Mediastinal Neoplasms / therapy. Retroperitoneal Neoplasms / therapy. Seminoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / therapeutic use. Combined Modality Therapy. Follow-Up Studies. Humans. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11283942.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Hapani S, Chu D, Wu S: Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report. J Med Case Rep; 2010;4:126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report.
  • CASE PRESENTATION: A 44-year-old Hispanic man with a primary mediastinal seminoma complicated by superior vena cava syndrome underwent treatment with four cycles of bleomycin, etoposide and cisplatin.
  • He had a complete positive response to the chemotherapy.
  • However, three months after treatment he presented with shortness of breath and severe hypoxemia associated with peripheral eosinophilia.
  • Computed tomography showed bilateral diffuse interstitial infiltrates that were refractory to antibiotic treatment.
  • CONCLUSION: This case illustrates that eosinophilic pneumonia may be a late sequela of bleomycin toxicity, and may respond dramatically to steroid treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1978 Jan;88(1):47-9 [74226.001]
  • [Cites] JAMA. 1976 Mar 22;235(12):1253-5 [55505.001]
  • [Cites] Eur J Cancer. 1972 Apr;8(2):205-15 [4116302.001]
  • [Cites] Cancer. 1973 Apr;31(4):903-14 [4122362.001]
  • [Cites] JAMA. 1976 Mar 15;235(11):1117-20 [55502.001]
  • [Cites] Cancer Treat Rep. 1982 Feb;66(2):359-62 [6173124.001]
  • [Cites] Semin Respir Crit Care Med. 2006 Apr;27(2):192-7 [16612770.001]
  • [Cites] Allergy. 2005 Jul;60(7):841-57 [15932372.001]
  • [Cites] Chest. 1985 Jul;88(1):103-6 [2408822.001]
  • [Cites] Am Rev Respir Dis. 1986 Feb;133(2):321-40 [3511808.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):34-51 [6176027.001]
  • [Cites] Chest. 2001 Aug;120(2):617-24 [11502668.001]
  • (PMID = 20429899.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2868877
  •  go-up   go-down


22. Chetaille B, Massard G, Falcoz PE: [Mediastinal germ cell tumors: anatomopathology, classification, teratomas and malignant tumors]. Rev Pneumol Clin; 2010 Feb;66(1):63-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal germ cell tumors: anatomopathology, classification, teratomas and malignant tumors].
  • Mediastinal germ cell tumors are rare tumors.
  • Each histological sub-type can be associated to another sub-type that realise a so-called mixed germ cell tumor.
  • Diagnosis strategy is currently well codified for malignant mediastinal germ cell tumors.
  • For instance, the treatment strategy still raises some specific problems to each histological type.
  • The treatment of seminomatous tumors is standardised--chemotherapy/surgery on residual tumor greater than 3 cm/radiotherapy on viable persistent residual tumors--and provides very satisfying results.
  • The treatment strategy is less standardised--association of chemotherapy and surgery--and the prognosis is very severe.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. Humans. Mediastinum / pathology. Neoplasm Invasiveness. Prognosis. Seminoma / classification. Seminoma / pathology. Seminoma / therapy. Teratoma / classification. Teratoma / pathology. Teratoma / therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20207298.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 18
  •  go-up   go-down


23. Snyder KM, Rubin MA, Shulkin BL, Hutchinson RJ, Wechsler DS: Mediastinal seminoma in a patient with Wiskott-Aldrich syndrome. J Pediatr Hematol Oncol; 2002 Nov;24(8):672-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal seminoma in a patient with Wiskott-Aldrich syndrome.
  • Shortness of breath developed in an 18-year-old man with Wiskott-Aldrich syndrome, and he was found to have a large mediastinal mass.
  • The gallium scan was positive, and biopsy indicated a seminoma.
  • After treatment with four cycles of chemotherapy, the mass completely resolved.
  • Despite severe thrombocytopenia, he required only two platelet transfusions during therapy.
  • Although lymphomas make up the vast majority of mediastinal tumors in patients with Wiskott-Aldrich syndrome, a positive gallium scan should not preclude the diagnosis of seminoma or the need for confirmatory tissue diagnosis.
  • This report shows the possibility of uneventful and successful treatment of malignancy in a patient with Wiskott-Aldrich syndrome and severe thrombocytopenia.
  • [MeSH-major] Mediastinal Neoplasms / etiology. Neoplastic Syndromes, Hereditary. Seminoma / etiology. Wiskott-Aldrich Syndrome
  • [MeSH-minor] Adolescent. Anaphylaxis / chemically induced. Anemia, Hemolytic, Autoimmune / complications. Anemia, Hemolytic, Autoimmune / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Gallium Radioisotopes. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immunocompromised Host. Immunoglobulins, Intravenous / adverse effects. Immunosuppressive Agents / adverse effects. Male. Prednisone / administration & dosage. Radiopharmaceuticals. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Wiskott Aldrich syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439043.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / N01 AI 75328
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 0 / Radiopharmaceuticals; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone
  •  go-up   go-down


24. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • Most of these nonteratomatous germ cell tumors other than yolk sac tumor were embryonal carcinoma, although rarely seminoma and choriocarcinoma were encountered.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Late recurrences were seen in many different sites in these patients, including the retroperitoneum, abdomen, pelvis, liver, mediastinum, lung, bone (femur, vertebra, and rib), lymph nodes outside the retroperitoneum and mediastinum (supraclavicular, neck, and axillary regions), scrotum and inguinal regions, adrenal gland, chest wall, and buttocks.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. Malagón HD, Valdez AM, Moran CA, Suster S: Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol; 2007 Sep;31(9):1356-62
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-three tumors arose in the mediastinum, 2 in the retroperitoneum, and 21 in the gonads.
  • The germ cell component consisted of pure mature or immature teratoma (23 cases), teratoma mixed with other seminomatous or nonseminomatous components (17), pure seminoma (2), intratubular germ cell neoplasia (1), and yolk sac tumor (1).
  • All patients were treated by cisplatinum-based chemotherapy plus other agents followed by surgery.
  • [MeSH-major] Immunohistochemistry. Mediastinal Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Sarcoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Orchiectomy. Ovariectomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721191.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ito S, Isowa N, Kikuchi R, Hasegawa S, Inui K, Wada H: [Mediastinal seminoma difficult to differentiate from thymoma through preoperative biopsy; report of a case]. Kyobu Geka; 2004 Oct;57(11):1070-3
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal seminoma difficult to differentiate from thymoma through preoperative biopsy; report of a case].
  • A case of a 36-year-old male patient with mediastinal seminoma is presented.
  • Chest computed tomography (CT) scan revealed a pulmonary nodule and an anteriormediastinal mass.
  • Complete surgical excision of the mediastinal mass was performed.
  • The final diagnosis was seminoma.
  • Additional postoperative chemotherapy (cisplatin + etoposide) was done.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Seminoma / pathology. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Male. Preoperative Care

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510825.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Tanabe T, Yasuo M, Tsushima K, Urushihata K, Yamamoto H, Hanaoka M, Koizumi T, Fujimoto K, Yamazaki Y, Hirose Y, Hamano H, Sakurai A, Kubo K: Mediastinal seminoma in a patient with multiple endocrine neoplasia type 1. Intern Med; 2008;47(18):1615-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal seminoma in a patient with multiple endocrine neoplasia type 1.
  • A patient with multiple endocrine neoplasia type 1 (MEN1) developed a mediastinal seminoma.
  • A diagnosis of mediastinal seminoma was pathologically confirmed and a complete remission was achieved by chemotherapy.
  • A diagnosis of MEN1 was made genetically.
  • Although patients with MEN1 manifest a variety of neoplastic disorders, no cases of concurrent seminoma and MEN1 have previously been reported.
  • In addition, no etiological relationship between seminoma and MEN1 has yet been reported.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Multiple Endocrine Neoplasia Type 1 / diagnosis. Neoplasms, Multiple Primary / diagnosis. Seminoma / diagnosis


28. Sung MT, Maclennan GT, Lopez-Beltran A, Zhang S, Montironi R, Cheng L: Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases. Am J Surg Pathol; 2008 Jan;32(1):146-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases.
  • Accurate diagnosis of mediastinal seminoma is critical because of its favorable response to radiation therapy and/or cisplatin-based chemotherapy.
  • Immunohistochemical staining for OCT4 has recently been validated as a powerful tool for detecting gonadal seminoma.
  • However, discrepancies between the genetic alterations and immunoprofiles of mediastinal and testicular seminomas have been reported, raising the question of whether techniques that are useful in the diagnosis of gonadal seminoma are applicable to its mediastinal counterpart.
  • The present study was conducted to evaluate the morphologic and immunohistochemical characteristics and chromosomal abnormalities of 12p in 23 primary mediastinal seminomas and to compare their applicability as diagnostic tools.
  • Lymphocytic infiltration is the most common histologic feature observed in primary mediastinal seminoma and both OCT4 immunostain and FISH for 12p abnormalities can be very helpful in diagnosing mediastinal seminoma.
  • The intense staining pattern of OCT4 and the high sensitivity of FISH make them superior to other auxiliary diagnostic utilities for detecting seminoma.
  • In addition, the incidences of cytokeratin expression of primary mediastinal seminoma are similar to those of its gonadal counterpart and pathologists must exercise caution in the interpretation of epithelial markers in mediastinal neoplasms.
  • [MeSH-major] Chromosomes, Human, Pair 12 / genetics. Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. Seminoma / genetics. Seminoma / pathology

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162782.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


29. Hsu YJ, Pai L, Chen YC, Ho CL, Kao WY, Chao TY: Extragonadal germ cell tumors in Taiwan: an analysis of treatment results of 59 patients. Cancer; 2002 Aug 15;95(4):766-74
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extragonadal germ cell tumors in Taiwan: an analysis of treatment results of 59 patients.
  • More investigations are warranted to define the optimal treatment.
  • Primary tumors occurred in the mediastinum (n = 27), retroperitoneum (n = 6), central nervous system (CNS; n = 24), and other sites (n = 2).
  • Patients received surgery, chemotherapy, radiotherapy, or a combination of treatment modalities as the primary treatment.
  • Three patients with mediastinal seminoma achieved complete remission (CR) and are alive with no evidence of disease (NED), with a median follow-up of 118 months.
  • Of 24 patients with mediastinal nonseminomas, 8 (33%) are alive with a median disease-free survival (DFS) period of 33 months.
  • Four patients with mediastinal nonsemonimas treated with salvage chemotherapy died.
  • CONCLUSIONS: The treatment results of our patients with seminomatous EGCT are comparable to those of Western countries.
  • However, the treatment results of patients with nonseminomatous EGCT are not as good.
  • The reason for this discrepancy needs to be explored for a better treatment outcome of for patients in Taiwan with EGCT.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Germinoma / therapy. Humans. Infant. Male. Middle Aged. Retrospective Studies. Survival Analysis. Taiwan. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10738
  • (PMID = 12209720.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Mickisch GH: Prognostic parameters for the management of advanced testis tumours. Curr Opin Urol; 2000 Sep;10(5):465-71
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the trend for an earlier and more accurate diagnosis amenable to curative treatment as well as the high effectiveness of standard Cisplatinum containing chemotherapy has masked the continuing need for intensifying therapy in patients with adverse risk factors.
  • This intense treatment is often associated with worrysome morbidity and the assessment of prognostic factors, stage by stage, is warranted on which patient at risk can be identified and treated accordingly.
  • Traditional prognostic factors, on which most classification systems are based, include large tumour volume, the presence of liver, bone or brain metastasis, grossly elevated tumour markers and an extragonadal primary site, particularly in the mediastinum.
  • Clearly, the infrastructure and the experience of the treating uro-oncology unit (see 1) is decisive for treatment outcomes, and -at least-'difficult to treat' patients should be referred to properly resourced cancer centres.
  • Finally, biologic factors (see 3) such as beta-human chorionic gonadotrophin or MAGE epitopes in seminoma or the percentage of embryonal carcinoma components orvascular invasion mayor may not inversely influence the prognosis and need further assessment in prospective trials.
  • However, the search for even better (molecular) biologic factors is speeding up because more complex treatment decisions such as in advanced testicular cancers rely on a more precise determination of prognosis, enabling a more tailored selection of individualized therapeutic options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005453.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 23
  •  go-up   go-down


31. Looijenga LH, Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW: Chromosomes and expression in human testicular germ-cell tumors: insight into their cell of origin and pathogenesis. Ann N Y Acad Sci; 2007 Dec;1120:187-214
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within the testis, three types of GCTs can be diagnosed: type I (teratomas and yolk-sac tumors of neonates and infants); type II (seminomas and nonseminomas); type III (spermatocytic seminomas).
  • Here the focus is on the type II GCTs, the most frequent type in the adult testis (so-called TGCTs).
  • They can also be diagnosed in dysgenetic gonads (an incomplete or defective formation of the gonad, caused by a disturbed process of migration of the germ cells and/or their correct organization in their fetal gonadal ridge), the anterior mediastinum, and pineal/suprasellar region.
  • With the exception of teratomas, most histological elements of TGCTs are sensitive for (cisplatin-based) chemotherapy; CIS/ITGCNU and seminoma cells are also sensitive to DNA damage induced by irradiation.
  • The unusual presence of wild-type P53 in TGCTs is explained by specific expression of a cluster of micro-RNAs (miRNAs), that is, hsa-miR 371-373, also expressed in ES cells, which prevents P53-driven cellular senescence upon oncogenic stress.
  • Demonstration of these characteristics, in combination with the knowledge of the abnormal niche of these cells, normally occupied by spermatogonia, allows an informative method for (early) diagnosis.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17911410.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 206
  •  go-up   go-down


32. Holdhoff M, Wung PK, Petronis JD, Couzi R: Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma. J Clin Oncol; 2007 Jun 10;25(17):2482-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Diseases / radionuclide imaging. Liver Neoplasms / secondary. Mediastinal Neoplasms / pathology. Seminoma / secondary
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoplasm, Residual. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1864-73 [11919246.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1497-503 [2778480.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1034-9 [15020605.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):e54-5 [17135635.001]
  • [Cites] Br J Urol. 1964 Jun;36:SUPPL:1-11 [14184707.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):454-60 [8636757.001]
  • (PMID = 17557961.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS573277; NLM/ PMC4036441
  •  go-up   go-down






Advertisement